Cybin Inc is a biotechnology company focused on developing innovative psychedelic-based therapeutic solutions to address various mental health disorders
The company is engaged in research and clinical development of psychedelic compounds, aiming to enhance mental health treatment options through advanced drug formulations and delivery methods. By leveraging the potential of psychedelics, Cybin strives to provide patients with new avenues for healing and improved quality of life, while also working to advance the understanding and acceptance of psychedelic therapies in mainstream medicine.
Cybin secures a U.S. patent for its CYB005 program targeting CNS disorders and prepares to launch a Phase 3 trial for CYB003 in major depressive disorder.
Maryland transitioned to an adult-use cannabis market a little over a year ago. Led by the state's Cannabis Administration Director, Will Tilburg, the transition resulted in the state's legal cannabis sales surpassing $1.1 billion in the first year following legalization. In August, Maryland Matters reported that Tilburg, who has spent six years working on the state's cannabis policy, announced his decision to step down from his current role on Dec.4, 2024.
As the premier gathering of top entrepreneurs and investors is taking place this Monday in New Jersey, let's scroll through the latest leadership changes in the cannabis and psychedelics industries.Cybin Inc.announced recently that Dr. Atul R. Mahableshwarkar M.D., DLFAPA, opted to join the company as senior vice president of clinical development. In addition, six cannabis companies announced changes to their respective boards of directors.
FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit, with CYBN, MNMD, and ATAI down. FDA not bound by decision.
